National Geographic’s nationally representative survey of 1,000 U.S. adults finds Americans prioritize health span over mere longevity: 64% would accept a shorter life if it meant their remaining years were disease‑free. While many are willing to make lifestyle changes, only a minority view aging as a medical condition and 72% worry about risks from experimental longevity technologies. Interest exists for FDA‑approved interventions (42% would take a daily cellular reprogramming pill), but most want cautious clinical testing and express ethical and equity concerns.
Most Americans Would Trade Years For Health, Cautious About Radical Anti‑Aging Treatments
A retiree plays golf in Sun City, Arizona, a sprawling retirement community northwest of Phoenix. A new survey shows that Americans are more interested in growing old gracefully—and perhaps a little more slowly—rather than attempting to reverse the aging process.David Klammer, laif/Redux
National Geographic commissioned a nationally representative survey of 1,000 U.S. adults, conducted by FINN Partners, to gauge how Americans view aging, what they might sacrifice for extra healthy years, and how open they are to experimental longevity technologies.
Key Findings
The survey shows a clear preference for health span — years lived free of physical and cognitive decline — over simply extending lifespan. A majority of respondents favor living fewer disease‑free years rather than a longer life burdened by frailty, and many express caution about cutting‑edge anti‑aging approaches.
What People Say They'd Give Up
About one‑third of respondents said they would give up alcohol forever if it guaranteed an extra 10 healthy years, while only 15% would forgo a favorite food. More than 20% said they would stop using social media, give up sugar, or give up caffeine for the same benefit. Nearly one‑fifth said they would not give up anything at all.
Attitudes Toward Treating Aging
Only 9% of respondents view aging as a medical condition that science should actively try to treat. Conversely, 61% said they would choose to pause their biological age at a specific year if they could, and 64% said they would accept a shorter life if it guaranteed their remaining years were free of decline.
Openness To Emerging Therapies — With Caveats
While most Americans prefer gradual, lifestyle-driven approaches, modest openness exists for new treatments if they prove safe and effective. Just over half said they would try at least one emerging longevity therapy if early human trials showed strong success. If such interventions reached FDA approval, respondents reported willingness as follows: 42% would take a daily cellular reprogramming pill, 27% would try senolytic drugs, 22% would consider blood plasma dilution, and 18% would accept organ replacement.
Concerns about safety tempered enthusiasm: when told about risks such as uncontrolled cell growth or cancer, 48% said clinical trials should proceed only with extreme caution, and just 13% said trials should move forward rapidly.
Financial And Social Tradeoffs
Longer lives raise financial worries: 63% said they fear outliving their financial safety net. Yet only 16% would delay retirement to gain 10 healthy years. If routinely living healthily past 120 were possible, 29% said retiring after age 70 would be acceptable.
Ethics, Equity, And Public Funding
About two‑thirds of respondents worry about the ethical risks of life‑extending technologies and the possibility that such treatments would be available only to the very wealthy. Sixty‑two percent said governments should not fund longevity research until basic healthcare is universally guaranteed. Opinions are mixed on societal impacts: 41% said living past 150 would be beneficial (citing added wisdom and contributions), while 25% raised concerns about overpopulation and economic strain.
Methodology: The survey polled 1,000 U.S. adults (18+) and was designed to be nationally representative by age, gender, and geographic region. Results reflect public opinion and do not constitute medical advice or scientific conclusions.
Author: Amy McKeever is a senior digital editorial manager at National Geographic.
Help us improve.
